A cut-off level of 5 ng/mL is used to define CEA elevation; cancer-specific mortality rates are higher and prognosis is poorer in patients with CRC showing preoperative serum CEA levels ≥5 ng/mL (44). The gene discussed is CEACAM5; the disease is cancer.